FY2025 EPS Estimates for Liquidia Raised by Lifesci Capital

Liquidia Corporation (NASDAQ:LQDA) – Equities research analysts at Lifesci Capital raised their FY2025 earnings per share estimates for shares of Liquidia in a research note issued on Monday, November 3rd. Lifesci Capital analyst C. Jubinville now forecasts that the company will post earnings per share of ($0.56) for the year, up from their prior forecast of ($1.89). The consensus estimate for Liquidia’s current full-year earnings is ($1.51) per share. Lifesci Capital also issued estimates for Liquidia’s Q4 2025 earnings at $0.29 EPS, Q1 2026 earnings at $0.53 EPS, Q2 2026 earnings at $0.62 EPS, Q3 2026 earnings at $0.85 EPS, Q4 2026 earnings at $0.95 EPS and FY2026 earnings at $2.76 EPS.

LQDA has been the topic of a number of other reports. Needham & Company LLC raised their target price on Liquidia from $36.00 to $52.00 and gave the company a “buy” rating in a research report on Tuesday. BTIG Research restated a “buy” rating and set a $49.00 target price on shares of Liquidia in a research report on Tuesday. Weiss Ratings restated a “sell (d-)” rating on shares of Liquidia in a research report on Wednesday, October 8th. Jefferies Financial Group reiterated a “buy” rating and issued a $45.00 price objective on shares of Liquidia in a report on Monday. Finally, Wells Fargo & Company assumed coverage on Liquidia in a report on Monday, October 20th. They issued an “overweight” rating and a $31.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $38.56.

Liquidia Price Performance

NASDAQ:LQDA opened at $26.42 on Thursday. Liquidia has a 52 week low of $9.71 and a 52 week high of $29.94. The company has a quick ratio of 2.41, a current ratio of 2.20 and a debt-to-equity ratio of 6.19. The stock has a market capitalization of $2.30 billion, a PE ratio of -18.35 and a beta of 0.12. The stock’s 50-day moving average price is $24.56 and its 200-day moving average price is $19.66.

Liquidia (NASDAQ:LQDA) last posted its earnings results on Monday, November 3rd. The company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.41. Liquidia had a negative return on equity of 296.78% and a negative net margin of 176.04%.The firm had revenue of $54.34 million for the quarter, compared to analysts’ expectations of $18.86 million. The firm’s revenue for the quarter was up 1106.7% compared to the same quarter last year.

Insiders Place Their Bets

In other Liquidia news, insider Rajeev Saggar sold 20,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 28th. The shares were sold at an average price of $27.85, for a total value of $557,000.00. Following the transaction, the insider directly owned 249,727 shares of the company’s stock, valued at $6,954,896.95. This trade represents a 7.41% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Raman Singh sold 45,524 shares of the firm’s stock in a transaction that occurred on Monday, September 15th. The stock was sold at an average price of $25.81, for a total transaction of $1,174,974.44. Following the completion of the transaction, the director directly owned 31,255 shares in the company, valued at $806,691.55. This trade represents a 59.29% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 849,141 shares of company stock worth $23,584,920. 26.50% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Bluefin Capital Management LLC purchased a new stake in shares of Liquidia during the 1st quarter valued at approximately $250,000. Boothbay Fund Management LLC raised its position in shares of Liquidia by 18.7% during the 1st quarter. Boothbay Fund Management LLC now owns 662,873 shares of the company’s stock valued at $9,777,000 after buying an additional 104,215 shares during the period. Adage Capital Partners GP L.L.C. raised its position in shares of Liquidia by 446.7% during the 1st quarter. Adage Capital Partners GP L.L.C. now owns 461,248 shares of the company’s stock valued at $6,803,000 after buying an additional 376,872 shares during the period. Y Intercept Hong Kong Ltd purchased a new stake in shares of Liquidia during the 2nd quarter valued at approximately $775,000. Finally, Bank of New York Mellon Corp raised its position in shares of Liquidia by 2.9% during the 1st quarter. Bank of New York Mellon Corp now owns 194,131 shares of the company’s stock valued at $2,863,000 after buying an additional 5,547 shares during the period. 64.54% of the stock is owned by hedge funds and other institutional investors.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).